

File No. 110127

Committee Item No. _____

Board Item No. 32

COMMITTEE/BOARD OF SUPERVISORS

AGENDA PACKET CONTENTS LIST

Board of Supervisors Meeting

Date February 8, 2011

Cmte Board

- | | | |
|--------------------------|-------------------------------------|--|
| <input type="checkbox"/> | <input type="checkbox"/> | Motion |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | Resolution |
| <input type="checkbox"/> | <input type="checkbox"/> | Ordinance |
| <input type="checkbox"/> | <input type="checkbox"/> | Legislative Digest |
| <input type="checkbox"/> | <input type="checkbox"/> | Budget Analyst Report |
| <input type="checkbox"/> | <input type="checkbox"/> | Legislative Analyst Report |
| <input type="checkbox"/> | <input type="checkbox"/> | Youth Commission Report |
| <input type="checkbox"/> | <input type="checkbox"/> | Introduction Form (for hearings) |
| <input type="checkbox"/> | <input type="checkbox"/> | Department/Agency Cover Letter and/or Report |
| <input type="checkbox"/> | <input type="checkbox"/> | MOU |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | Grant Information Form |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | Grant Budget |
| <input type="checkbox"/> | <input type="checkbox"/> | Ethics Form 126 |
| <input type="checkbox"/> | <input type="checkbox"/> | Subcontract Budget |
| <input type="checkbox"/> | <input type="checkbox"/> | Contract/Agreement |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | Award Letter |
| <input type="checkbox"/> | <input type="checkbox"/> | Application |
| <input type="checkbox"/> | <input type="checkbox"/> | Public Correspondence |

OTHER

(Use back side if additional space is needed)

<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____

Completed by: Andrea Ausberry Date February 3, 2011

Completed by: _____ Date _____

An asterisked item represents the cover sheet to a document that exceeds 25 pages.
The complete document is in the file.

1 [Accept and Expend Grant - Western States Node of the National Drug Abuse Treatment
2 Clinical Trials Network - \$16,876]

3
4 **Resolution authorizing the Department of Public Health to retroactively accept and**
5 **expend a grant in the amount of \$16,876 from the University of California San**
6 **Francisco to participate in a program entitled "Western States Node of the National**
7 **Drug Abuse Treatment Clinical Trials Network" for the period of September 1, 2010,**
8 **through August 31, 2011.**

9
10 WHEREAS, UCSF is the recipient of a grant award from the National Institutes of
11 Health supporting the Western States Node of the National Drug Abuse Treatment Clinical
12 Trials Network; and,

13 WHEREAS, With a portion of these funds, UCSF has subcontracted with DPH in the
14 amount of \$16,876 for the period of September 1, 2010 through August 31, 2011; and,

15 WHEREAS, As a condition of receiving the grant funds, UCSF requires the City to
16 enter into an agreement (the "Agreement"), a copy of which is on file with the Clerk of the
17 Board of Supervisors in File No.110127; which is hereby declared to be a part of this
18 resolution as if set forth fully herein; and,

19 WHEREAS, An ASO amendment is not required as the grant partially reimburses DPH
20 for one existing position, one Senior Physician Specialist (Job Class 2232) at .05 FTE, for the
21 period of September 1, 2010 through August 31, 2011; and,

22 WHEREAS, A request for retroactive approval is being sought because DPH did not
23 receive notification of the contract until December 13, 2010 for a project start date of
24 September 1, 2010; and,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

WHEREAS, The budget includes a provision for indirect costs in the amount of \$1,808; now, therefore, be it

RESOLVED, That DPH is hereby authorized to accept and expend a grant retroactively in the amount of \$16,876 from UCSF; and, be it

FURTHER RESOLVED, That DPH is hereby authorized to retroactively accept and expend the grant funds pursuant to San Francisco Administrative Code section 10.170-1; and, be it

FURTHER RESOLVED, That the Director of Health is authorized to enter into the agreement on behalf of the City.

RECOMMENDED:

APPROVED:

Signature on file

Signature on file

Barbara Garcia, MPA
Director of Health

Office of the Mayor

Signature on file

Office of the Controller



Edwin Lee
Mayor

Barbara Garcia, MPA
Director of Health

TO: Angela Calvillo, Clerk of the Board of Supervisors

FROM: Barbara Garcia, MPA
Director of Health

DATE: January 12, 2011

SUBJECT: Grant Accept and Expend

GRANT TITLE: Western States Node of the National Drug Abuse
Treatment Clinical Trials Network - \$16,876

Attached please find the original and 4 copies of each of the following:

- Proposed grant resolution, original signed by Department
- Grant information form, including disability checklist -
- Budget and Budget Justification
- Grant application: Not Applicable. No application submitted. Asked to participate in the project.
- Agreement / Award Letter
- Other (Explain):

Special Timeline Requirements:

Departmental representative to receive a copy of the adopted resolution:

Name: Richelle-Lynn Mojica

Phone: 255-3555

Interoffice Mail Address: Dept. of Public Health, Office of Quality Management for
Community Programs, 1380 Howard St.

Certified copy required Yes

No

File Number: 110127
(Provided by Clerk of Board of Supervisors)

Grant Information Form
(Effective March 2005)

Purpose: Accompanies proposed Board of Supervisors resolutions authorizing a Department to accept and expend grant funds.

The following describes the grant referred to in the accompanying resolution:

1. Grant Title: Western States Node of the National Drug Abuse Treatment Clinical Trials Network
2. Department: Department of Public Health
HIV Prevention Section
3. Contact Person: Grant Colfax Telephone: 554-9173
4. Grant Approval Status (check one):
 Approved by funding agency Not yet approved
5. Amount of Grant Funding Approved or Applied for: \$16,876
- 6a. Matching Funds Required: \$0
b. Source(s) of matching funds (if applicable):
- 7a. Grant Source Agency: National Institutes of Health
b. Grant Pass-Through Agency (if applicable): The Regents of the University of California
8. Proposed Grant Project Summary: Co-principal Investigator will be involved in the analysis, writing, and dissemination of the project's findings.
9. Grant Project Schedule, as allowed in approval documents, or as proposed:
Start-Date: 09/01/2010 End-Date: 08/31/2011
- 10a. Amount budgeted for contractual services: No
b. Will contractual services be put out to bid? N/A
c. If so, will contract services help to further the goals of the department's MBE/WBE requirements? N/A
d. Is this likely to be a one-time or ongoing request for contracting out? N/A
- 11a. Does the budget include indirect costs? Yes No
b1. If yes, how much? \$1,808
b2. How was the amount calculated? 12% of modified direct costs
c. If no, why are indirect costs not included?
 Not allowed by granting agency To maximize use of grant funds on direct services
 Other (please explain):
c2. If no indirect costs are included, what would have been the indirect costs?
12. Any other significant grant requirements or comments:

We respectfully request for approval to accept and expend these funds retroactive to September 1, 2010. The Department received the subcontract agreement on December 13, 2010.

Grant Code is: HCAO37/11


****Disability Access Checklist****

13. This Grant is intended for activities at (check all that apply):

- | | | |
|--|---|--|
| <input checked="" type="checkbox"/> Existing Site(s) | <input type="checkbox"/> Existing Structure(s) | <input type="checkbox"/> Existing Program(s) or Service(s) |
| <input type="checkbox"/> Rehabilitated Site(s) | <input type="checkbox"/> Rehabilitated Structure(s) | <input checked="" type="checkbox"/> New Program(s) or Service(s) |
| <input type="checkbox"/> New Site(s) | <input type="checkbox"/> New Structure(s) | |

14. The Departmental ADA Coordinator and/or the Mayor's Office on Disability have reviewed the proposal and concluded that the project as proposed will be in compliance with the Americans with Disabilities Act and all other Federal, State and local access laws and regulations and will allow the full inclusion of persons with disabilities, or will require unreasonable hardship exceptions, as described in the comments section:

Comments:

Departmental or Mayor's Office of Disability Reviewer:  _____
Jason Hashimoto

Date Reviewed: 1/19/11

Department Approval:  _____
Barbara Garcia, MPA Director of Public Health

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH

AIDS Office

HIV Prevention Section

Western States Node of the International Drug Abuse Treatment Clinical Trials Network

9/1/2010 - 8/31/2011

Dept / Div: HPH-03
 Fund Group: 2S/CHS/GNC
 Index Code: HCHPDHIVSVGR
 Grant Code: HCD136
 Grant Detail: 1100

CATEGORY/LINE ITEM	Annual Salary	30.00% Annual Frin Ben	Total Annual Sal/Frin Ben	% OF TIME	% OF FTE	Monthly Rate	Mth	Salary Budget	Frin Ben Budget	Total Budget	Comments
A. PERSONNEL											
1. Senior Physician Specialist 2232 7 G. Colfax	183,092	54,928	238,020	5%	0.05	15,258	12	9,155	2,746	11,901	.05 pd11, .65 pd90, .05 d116, .10 d135, .05 d137, .05 d138, .05 ao37
2. COLA 4%								0	1	1	
3. STEP 5%								0	0	0	
TOTAL PERSONNEL:	183,092	54,928	238,020		0.05			9,155	2,747	11,902	

TOTAL PERSONNEL: 183,092 54,928 238,020 0.05

00101 SALARIES:
 00103 MANDATORY FRINGE:
 TOTAL PERSONNEL:

9,155
 2,747
11,902

C. TRAVEL
 1. Local Travel (02301)
 2. Out-of-Jurisdiction Travel(02101)
 Sub Total TRAVEL

0
 0
0

D. EQUIPMENT
 1. Equipment (06061)
 Sub Total EQUIPMENT

0
 0
0

E. MATERIALS AND SUPPLIES
 1. Office supplies (04951)
 Sub Total SUPPLIES

0
 0
0

F. CONTRACTUAL SERVICES (02789)
 1. PHFE
 Sub Total CONTRACTS

0
 0
0

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH
AIDS Office

HIV Prevention Section
Western States Node of the International Drug Abuse Treatment Clinical Trials Network
9/1/2010 - 8/31/2011

Dept / Div: HPH-03
Fund Group: 2S/CHS/GNC
Index Code: HCHPDHVSVGR
Grant Code: HCD136
Grant Detail: 1100

CATEGORY/LINE ITEM	Annual Salary	30.00% Annual Frin Ben	Total Annual Sal/Frin Ben	% OF TIME	% OF FTE	Monthly Rate	Mth	Salary Budget	Frin Ben Budget	Total Budget	Comments
--------------------	---------------	------------------------	---------------------------	-----------	----------	--------------	-----	---------------	-----------------	--------------	----------

- G. OTHER
1. Rent support/mtg fac (081RR) 3,166
 2. Telephone/Com (081ET) 0
 3. IRB fees (02699) 0
 4. Courier/Delivery Service (03521) 0
 5. Print/Slide Production - Outside (03552) 0
- Sub TOTAL OTHER 3,166

TOTAL DIRECT COST 15,068

BUDGET SUMMARY

A. TOTAL SALARIES	9,155
B. TOTAL FRINGE	2,747
C. TRAVEL	0
D. EQUIPMENT	0
E. MATERIALS AND SUPPLIES	0
F. CONTRACT / MOU	0
G. OTHER	3,166
DIRECT COSTS	15,068
H. INDIRECT COST (12% of total modified direct costs)	1,808
TOTAL BUDGET	16,876
AWARD	16,876
SURPLUS/(DEFICIT)	(0)



San Francisco Department of Public Health (SFDPH)
AIDS Office
HIV Prevention Section

Western States Node of the National Drug Abuse Treatment Clinical Trials Network

BUDGET JUSTIFICATION
(September 1, 2010 – August 31, 2011)

A.	PERSONNEL	
B.	MANDATORY FRINGE	
1.	0.05 2232 – Sr. Physician Specialist: Grant Colfax	
	Twelve Month Salary	\$9,155
	Mandatory Fringe Benefits (@ 30%) =	\$2,747
		\$11,902
	Dr. Grant Colfax will involve in the analysis, writing and dissemination of the project's findings. Include initiation and co-authorship of publications and presentation of findings of scientific and community venues.	
	Total Salaries	\$9,155
	Total Fringe	\$2,747
	TOTAL PERSONNEL:	\$11,902
C.	TRAVEL	\$0
D.	EQUIPMENT	\$0
E.	SUPPLIES	\$0
F.	CONTRACTUAL	\$0
G.	OTHER	\$3,166
	TOTAL DIRECT COSTS	\$15,068
H.	INDIRECT COSTS (12% of total modified direct costs)	\$1,808
	TOTAL BUDGET:	\$16,876

Subaward Agreement

Prime Awardee		Subawardee	
Institution/Organization ("UNIVERSITY") Name: The Regents of the University of California Address: Office of Sponsored Research Division of Contracts and Grants University of California, San Francisco 3333 California Street, Suite 315 San Francisco, CA 94143-0962 University's PI: James L. Sorensen, PhD		Institution/Organization ("COLLABORATOR") Name: City and County of San Francisco Address: 1380 Howard Street, 4 th Floor San Francisco, CA 94103 EIN: 94-6000417 Subcontractor's PI: Grant Colfax, MD	
Prime Award Number: U10 DA015815-09 Revised UCSF DPA / Fund Numbers: 444653 / 29408 CFDA Number: 93.279		Subaward: 6422sc	
Awarding Agency: National Institutes of Health – National Institute on Drug Abuse			
Period of Performance: 9/1/2010 through 8/31/2011		Amount Funded this Action: \$16,876.00	
Est. Budget for Total Project \$33,751.00			
Project Title: Western States Node of the National Drug Abuse Treatment Clinical Trials Network			
Reporting Requirements [Check here if applicable: <input checked="" type="checkbox"/> See Attachment 4]			
Terms and Conditions			
Unless otherwise stated in this Agreement, these standard terms and conditions shall apply.			
1) University hereby awards a cost reimbursable subaward, as described above, to Collaborator. The scope of work and budget for this subaward are detailed in Attachments 5 and 6. In its performance of subaward work, Collaborator shall be an independent entity and not an employee or agent of University.			
2) University shall reimburse Collaborator not more often than monthly for allowable costs. All invoices shall be submitted using Collaborator's standard invoice, but at a minimum shall include current and cumulative costs (including cost sharing), subaward number, and certification as to truth and accuracy of invoice. <i>Invoices that do not reference University's subaward number shall be returned to Collaborator.</i> Invoices and questions concerning invoice receipt or payments should be directed to the appropriate party's Financial Contact, as shown in Attachment 3.			
3) A final statement of cumulative costs incurred, including cost sharing, marked "FINAL," must be submitted to University's Financial Contact NOT LATER THAN forty-five (45) days after subaward end date. The final statement of costs shall constitute Collaborator's final financial report.			
4) All payments shall be considered provisional and subject to adjustment within the total estimated cost in the event such adjustment is necessary as a result of an adverse audit finding against the Collaborator.			
5) Matters concerning the technical performance of this subaward should be directed to the appropriate party's Project Director, as shown in Attachment 3. Technical reports are required as shown above, "Reporting Requirements."			
6) Matters concerning the request or negotiation of any changes in the terms, conditions, or amounts cited in this subaward agreement, and any changes requiring prior approval, should be directed to the appropriate party's Authorized Official, as shown in Attachment 3. Any such changes made to this subaward agreement require the written approval of each party's Authorized Official, as shown in Attachment 3.			
7) Each party shall be responsible for its negligent acts or omissions and the negligent acts or omissions of its employees, officers, or directors, to the extent allowed by law.			
8) Either party may terminate this agreement with thirty days written notice to the appropriate party's Administrative Contact, as shown in Attachment 3. University shall pay Collaborator for termination costs as allowable under OMB Circular A-21 or A-122, as applicable.			
9) No-cost extensions require the approval of the University. Any requests for a no-cost extension should be addressed to and received by the Principal Investigator, as shown in Attachment 3, not less than thirty days prior to the desired effective date of the requested change.			
10) The Subaward is subject to the terms and conditions of the Prime Award and other special terms and conditions as identified in Attachment 2.			
11) By signing below Collaborator makes the certifications and assurances shown in Attachments 1 and 2.			
By an Authorized Official of UNIVERSITY:  Regnier Jurado Manager, Subcontracts Team Office of Sponsored Research		By an Authorized Official of COLLABORATOR:  Name: Barbara Garcia Title: Deputy Director of Health	
Date: 12/08/10		Date: 12/14/10	

6422sc

**Attachment 1
Subaward Agreement**

Certification Regarding Lobbying

1) No Federal appropriated funds have been paid or will be paid, by or on behalf of the Collaborator, to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with the awarding of any Federal contract, the making of any Federal grant, the making of any Federal loan, the entering into of any cooperative agreement, and the extension, continuation, renewal, amendment, or modification of any Federal contract, grant, loan, or cooperative agreement.

2) If any funds other than Federal appropriated funds have been paid or will be paid to any person for influencing or intending to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with this Federal contract, grant, loan, or cooperative agreement, the Collaborator shall complete and submit Standard Form -LLL, "Disclosure Form to Report Lobbying," to the University.

3) The Collaborator shall require that the language of this certification be included in the award documents for all subawards at all tiers (including subcontracts, subgrants, and contracts under grants, loans, and cooperative agreements) and that all subrecipients shall certify and disclose accordingly.

This certification is a material representation of fact upon which reliance was placed when this transaction was made or entered into. Submission of this certification is a prerequisite for making or entering into this transaction imposed by section 1352, title 31, U. S. Code. Any person who fails to file the required certification shall be subject to a civil penalty of not less that \$10,000 and not more that \$100,000 for each such failure.

Debarment, Suspension, and Other Responsibility Matters

Collaborator certifies by signing this Subaward Agreement that neither it nor its principals are presently debarred, suspended, proposed for debarment, declared ineligible or voluntarily excluded from participation in this transaction by any federal department or agency.

OMB Circular A-133 Assurance

Collaborator assures University that it complies with A-133 and that it will notify University of completion of required audits and of any adverse findings which impact this subaward.

Attachment 2
Subaward Agreement
NIH

Agency-Specific Certifications/Assurances

1. The following assurances/certifications are made and verified by Collaborator's Authorized Official on the face page of this Subaward. Descriptions of individual assurances/certifications are provided in Section III of the PHS 398. 1) Human Subjects; 2) Research Using Human Embryonic Stem Cells; 3) Research on Transplantation of Human Fetal Tissue; 4) Women and Minority Inclusion Policy; 5) Inclusion of Children Policy; 6) Vertebrate Animals; 7) Debarment and Suspension; 8) Drug-Free Workplace; 9) Lobbying; 10) Non-Delinquency on Federal Debt; 11) Research Misconduct; 12) Civil Rights (Form HHS 441 or HHS 690); 13) Handicapped Individuals (Form HHS 641 or HHS 690); 14) Sex Discrimination (Form HHS 639-A or HHS 690); 15) Age Discrimination (Form HHS 680 or HHS 690); 16) Recombinant DNA and Human Gene Transfer Research; 17) Financial Conflict of Interest; 18) Smoke Free Workplace; 19) Prohibited Research; 20) Select Agent Research; 21) PI Assurance.

General terms and conditions:

1. The restrictions on the expenditure of federal funds in appropriations acts are applicable to this subaward to the extent those restrictions are pertinent.
2. 45 CFR Part 74 or 45 CFR Part 92 as applicable. [This is the CFR governing NIH.]
3. The NIH Grants Policy Statement, including addenda, in effect as of the beginning date of the period of performance and found at <http://grants.nih.gov/grants/policy/policy.htm>, except for the payment mechanism and final reporting requirements are replaced with Reporting Requirements and Terms and Conditions on the front page of this agreement.
4. **This paragraph applies only if the prime grant was awarded under expanded authorities.** Expanded Authorities apply, except for the right to initiate an automatic one-time extension of the end date, which is replaced by the need to obtain prior written approval from the University. Any prior approvals are to be sought from the University and not the Federal Awarding Agency.
5. Collaborator assures, by signing this Subaward Agreement, that all Collaborator's personnel who are responsible for the design and conduct of projects involving human research participants have successfully completed their institutional training in accordance with the NIH Guide, Notice OD-00-039.
6. Title to equipment costing \$5,000 or more that is purchased or fabricated with research funds or collaborator cost sharing funds, as direct costs of the project or program, shall unconditionally vest in the collaborator upon acquisition without further obligation to the Federal Awarding Agency subject to the conditions specified in the NIH Grants Policy Statement.

Special terms and conditions:

1. **Copyrights**
Collaborator grants to University an irrevocable, royalty-free, non-transferable, non-exclusive right and license to use, reproduce, make derivative works, display, and perform publicly any copyrights or copyrighted material (including any computer software and its documentation and/or databases) first developed and delivered under this Subaward Agreement solely for the purpose of and only to the extent required to meet University's obligations to the Federal Government under its Prime Award.
2. **Data Rights**
Collaborator grants to University the right to use data created in the performance of this Subaward Agreement solely for the purpose of and only to the extent required to meet University's obligations to the Federal Government under its Prime Award.

3. Objectivity in Research

Collaborator hereby assures University that it has implemented a policy on conflict of interest that complies with the federal regulations on Objectivity in Research, 42 CFR 50, Subpart F. Collaborator's policy will be made applicable to activities under this award. If Collaborator does not have a conflict of interest policy, it agrees to develop a policy. Collaborator also certifies that to the best of Collaborator's knowledge, all financial disclosures related to the activities funded by this Agreement have been made. Disclosures must be made by all persons who have responsibility for the design, conduct or reporting of the research. Prior to Collaborator's expenditure of any funds under this Award, Collaborator will report to University the existence of a conflict of interest (but not the nature of the interest or other details) found by Collaborator and assure that the conflict of interest has been managed, reduced or eliminated in accordance with the PHS regulations. For any interest that Collaborator identifies as conflicting subsequent to Collaborator's initial report under this award, the report will be made and the conflicting interest managed, reduced, or eliminated, at least on an interim basis, within thirty (30) days of that identification. *The report must include the following information: (a) Grant/contract number; (b) Name of the PI; (c) Name of the investigator (if different from PI) with the conflict of interest; and (d) Which method was used to protect the involved PHS funded research from bias (eg, managed, reduced, or eliminated). The report should be made to the following University official:*

University Official: (For receipt of information regarding objectivity in research only - NOT for receipt of subcontract)	COI Coordinator, Campus Box 0962 UCSF, Office of Sponsored Research 3333 California Street, Suite 320 San Francisco, CA 94143-0962 If sent by Fed Ex or UPS, the zip code is 94118
--	--

4. As required in its annual appropriations act, NIH, AHRQ and SAMSHA will not reimburse grantees for the Direct salaries of individuals at a rate in excess of the level specified in the annual appropriations language. Accordingly, none of the funds awarded under this Agreement shall be used to pay the salary of an individual at a rate in excess of the amount allowed under Federal law. This limitation applies to any subcontracts under any tier under this Agreement.
5. Hereby incorporated as part of this agreement is the project Scope of Work, included as Attachment 5.
6. Hereby incorporated as part of this agreement is the project Budget, included as Attachment 6.
7. Hereby incorporated as part of this agreement is the Notice of Grant Award as Attachment 7.
8. Carry over of an unobligated balance into the next budget period requires University Principal Investigator prior approval and subsequent formal amendment to this agreement.

YES X NO

9. Cost Sharing

If this agreement contains cost share commitments (either voluntary, committed, or mandatory) then the subrecipient hereby certifies that it has systems and/or processes in place for tracking cost sharing, and will meet all cost share commitments under this agreement.

**Attachment 3
Subaward Agreement**

University Contacts	Collaborator Contacts
Administrative Contact (Departmental) Name: Barbara Paschke Address: UCSF Box 0852 San Francisco, CA 94143 Telephone: 415-437-3032 Email: Barbara.paschke@ucsf.edu	Administrative Contact (Departmental) Name: Diana Cheung Address: City and County of San Francisco, Department of Public Health 1380 Howard Street, 4 th Floor San Francisco, CA 94103 Telephone: 415-255-3702 Email: Diana.cheung@sfdph.org
Principal Investigator Name: Dr. James L. Sorensen Address: UCSF Box 0852 San Francisco, CA 94143 Telephone: 415-206-3969 Email: James.Sorensen@ucsf.edu	Project Director Name: Dr. Grant Colfax Address: City and County of San Francisco, Department of Public Health 1380 Howard Street, 4 th Floor San Francisco, CA 94103 Telephone: 415-554-9173 Email: grant.colfax@sfdph.org
Financial Contact Name: Accounts Payable Subcontract Payment Desk Address: UCSF Controller's Office 1855 Folsom Street, #425 San Francisco, CA 94143-0812 Telephone: 415-476-2126 Fax: 415-682-7403 Email: Subcontract@ucsf.edu	Financial Contact Name: Address: Telephone: Fax: Email:
Authorized Official Name: Regnier Jurado Manager, Subcontracts Team Address: UCSF Office of Sponsored Research 3333 California Street, Suite 315 San Francisco, CA 94143-0962 Telephone: 415-476-2782 Fax: 415-476-8158 Email: Regnier.Jurado@ucsf.edu	Authorized Official Name: Address: Telephone: Fax: Email:

**Attachment 4
Subaward Agreement**

Reporting Requirements

The Following checked Reporting Requirements apply to this Subaward Agreement:

 X Collaborator agrees to submit interim progress reports if continuation is intended beyond the Termination Date and shall be submitted 90 (ninety) days before the end of the reporting period. Terminal progress reports must be submitted to University within 45 (forty-five) days after the Termination Date of this Agreement. The report should include a summary statement of progress toward the achievement of the originally stated aims, a list of the positive and negative results which are considered to be significant by the Project Director, and a list of publications resulting from the project with plans (if any) for further publication. All progress reports shall be submitted to University's Principal Investigator.

 Collaborator agrees to submit monthly technical/progress reports to University's Project Director identified in Attachment 3.

 Collaborator agrees to submit quarterly technical/progress reports within thirty (30) days From end of each project quarter to University's Project Director identified in Attachment 3.

 X Patent rights for Subcontractor shall be in accordance with P.L. 98-620, Patent Rights (Small Business Firms and Nonprofit Organizations), as implemented by 37 CFR Chapter IV, Part 401. Subcontractor shall promptly and fully report directly to NIH all inventions conceived or made and reduced to practice under this Agreement. Subcontractor shall submit a copy of the transmittal letter of any such report to University and shall include this Agreement Number along with transmittal. Within ninety (90) days following expiration or termination of this agreement Subcontractor shall submit to University a final invention report.

 (Applicable NASA Grants) The Collaborator agrees to submit to University's Administrative Contact identified in Attachment 3, NASA Form 1679 "New Technology Disclosure" for each discovery of new technology individually and at the time of its Discovery. For a multi-year Subaward Agreement, Collaborator agrees to summarize the Previous year's disclosures on an annual basis by completing NASA Form C-3044, New Technology Summary Report and marking it Interim. The first Interim New Technology Summary Report is due exactly twelve (12) months from the effective date of the Subaward Agreement and anniversary thereafter.

- NASA Form 1679 and NASA Form C-3044 can be located at:
<http://tco.gsfc.nasa.gov/>

 (Applicable EPA Grants) Collaborator agrees to submit to University's Administrative Contact identified in Attachment 3, EPA Form 5700-52A "Minority Business Enterprises/Women-Owned Business Enterprises."

- EPA Form 5799-52A can be located at:
<http://www.epa.gov/osdbu/>

Attachment 5
SCOPE OF WORK

**SCOPE OF WORK STATEMENT
SUBCONTRACT WITH THE CITY AND COUNTY OF SAN FRANCISCO**

Project Title: CTN 0032: HIV Rapid Testing & Counseling in Drug Abuse Treatment Programs in the U.S

Node PI of UCSF Award: James L. Sorensen, Ph.D.

UCSF prime grant: #U10 DA15815

Subcontractee Institution: City and County of San Francisco (CCSF)

PI of CCSF Subcontract: Grant Colfax, M.D.

Period of Performance: September 1, 2010 to August 31, 2011

Grant Colfax, MD of the San Francisco Department of Public Health- AIDS Office is the co-Principal Investigator for this project, which has completed all recruitment and follow-up. He will be involved in the analysis, writing, and dissemination of the project's findings. This will include initiation and co-authorship of publications and presentation of findings at scientific and community venues.

Attachment 6

BUDGET

Contract of Prime UCSF Grant Sorensen, James
 if Investigator of Subcontract Colfax, Grant

DETAILED BUDGET FOR INITIAL BUDGET PERIOD				FROM	THROUGH			
CCSF - CTN 32 DIRECT and F&A COSTS				9/1/2010	8/31/2011			
PERSONNEL (Applicant organization only)	NAME	ROLE ON PROJECT	Devoted to		DOLLAR AMOUNT REQUESTED (omit cents)			
			Cal Mths	INST BASE SALARY	SALARY REQUESTED	FRINGE BENEFITS	TOTAL	
	Grant Colfax	PI of Subcontract	0.60	183,092	9,155	2,747	11,902	
* Includes Key Personnel ** Other Significant Contributor + Federal Salary Cap of \$189,700 Observed				SUBTOTALS	\$9,155	\$2,747	\$11,902	
CONSULTANT COSTS								0
EQUIPMENT (Itemize)								0
SUPPLIES (Itemize by category)								0
TRAVEL								0
PATIENT CARE COSTS								0
INPATIENT OUTPATIENT								0
ALTERATIONS AND RENOVATIONS (Itemize by category)								0
OTHER EXPENSES (Itemize by category)								0
Rent of project space							3,166	
								3,166
CONSORTIUM/CONTRACTUAL DIRECT COSTS within this budget					DIRECT COSTS		\$0	
SUBCONTRACTOR'S SUBTOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD for							\$15,068	
CONSORTIUM/CONTRACTUAL F&A COSTS within this budget					F&A COSTS		\$0	
SUBCONTRACTOR'S F&A COSTS based on					\$15,068 @	12%	DC	\$1,808
TOTAL DIRECT + F&A COSTS FOR INITIAL BUDGET PERIOD								\$16,876

Attachment 7

NOGA



Grant Number: 2U10DA015815-09 REVISED

Principal Investigator(s):
DENNIS MCCARTY
JAMES L SORENSEN (contact), PHD

Project Title: Western States Node of the National Drug Abuse Treatment Clinical Trials Network

JOYCE ABE
CONTRACTS & GRANTS OFFICER
UNIV OF CALIFORNIA, SAN FRANCISCO
OFFICE OF SPONSORED RESEARCH
3333 CALIFORNIA STREET, STE 315
SAN FRANCISCO, CA 941430962

Award e-mailed to: cgrasteam@ucsf.edu

Budget Period: 09/01/2010 – 08/31/2011
Project Period: 09/30/2002 – 08/31/2015

Dear Business Official:

The National Institutes of Health hereby revises this award (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF CALIFORNIA SAN FRANCISCO in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 & 6306 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release or other document that cites results from NIH grant-supported research must include an acknowledgment of NIH grant support and disclaimer such as "The project described was supported by Award Number U10DA015815 from the National Institute On Drug Abuse. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute On Drug Abuse or the National Institutes of Health."

Award recipients are required to comply with the NIH Public Access Policy. This includes submission to PubMed Central (PMC), upon acceptance for publication, an electronic version of a final peer-reviewed, manuscript resulting from research supported in whole or in part, with direct costs from National Institutes of Health. The author's final peer-reviewed manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process. For additional information, please visit <http://publicaccess.nih.gov/>.

Award recipients must promote objectivity in research by establishing standards to ensure that the design, conduct and reporting of research funded under NIH-funded awards are not biased by a conflicting financial interest of an Investigator. Investigator is defined as the Principal Investigator and any other person who is responsible for the design, conduct, or reporting of NIH-funded research or proposed research, including the Investigator's spouse and dependent children. Awardees must have a written administrative process to identify and manage financial conflict of interest and must inform Investigators of the conflict of interest policy and of the Investigators' responsibilities. Prior to expenditure of these awarded funds, the Awardee must report to the NIH Awarding Component the existence of a conflicting interest and within 60 days of any new conflicting interests identified after the initial report. Awardees must comply with these and all other aspects of 42 CFR Part 50, Subpart F. These requirements also apply to subgrantees, contractors, or collaborators engaged by the Awardee under this award. The NIH website <http://grants.nih.gov/grants/policy/foi/index.htm> provides additional information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Deborah S Wertz
Grants Management Officer
NATIONAL INSTITUTE ON DRUG ABUSE

Additional information follows

SECTION I – AWARD DATA – 2U10DA015815-09 REVISED

Award Calculation (U.S. Dollars)

Salaries and Wages	\$299,460
Fringe Benefits	\$76,685
Personnel Costs (Subtotal)	\$376,145
Consultant Services	\$10,000
Supplies	\$3,975
Travel Costs	\$50,375
Other Costs	\$55,949
Consortium/Contractual Cost	\$1,103,362

Federal Direct Costs	\$1,599,806
Federal F&A Costs	\$182,115
Approved Budget	\$1,781,921
Federal Share	\$1,781,921
Less Unobligated Balance	\$638,174
TOTAL FEDERAL AWARD AMOUNT	\$1,143,747

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$0

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
9	\$1,143,747	\$1,143,747
10	\$1,135,271	\$1,135,271
11	\$1,121,304	\$1,121,304
12	\$1,120,441	\$1,120,441
13	\$1,120,441	\$1,120,441

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Number: 93.279
 EIN: 1946036493A6
 Document Number: UDA015815C
 Fiscal Year: 2010

IC	CAN	2010	2011	2012	2013	2014
DA	8472653	\$1,143,747	\$1,135,271	\$1,121,304	\$1,120,441	\$1,120,441

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: CT/RDD / OC: 414M / Processed: WERTZD 11/04/2010

SECTION II – PAYMENT/HOTLINE INFORMATION – 2U10DA015815-09 REVISED

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 2U10DA015815-09 REVISED

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.

- d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at '<http://grants.nih.gov/grants/policy/awardconditions.htm>' for certain references cited above.)

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase V Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register "applicable clinical trials" on the ClinicalTrials.gov Protocol Registration System Information Website. NIH encourages registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/

This award provides support for one or more NIH defined Phase III Clinical Trials. The NIH Policy for research supported as an NIH Phase III Clinical Trial has been amended in Section II.B. of the NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research – Amended October 2001 (see http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm).

A description of plans to conduct analyses, as appropriate, by sex/gender and racial/ethnic groups must be included in clinical trial protocols. Cumulative subject accrual and progress in conducting subset analyses must be reported to NIH in the annual Progress Reports. Final analyses of sex/gender and racial/ethnic differences must be reported in the required Final Progress Report or Competitive Renewal Applications (or Contract Renewals/Extensions) as stated in Section II.B. of the Guidelines.

**Treatment of Program Income:
Additional Costs**

SECTION IV – DA Special Terms and Conditions – 2U10DA015815-09 REVISED

This revision supersedes Notice of Grant Award (NGA) issued 08/30/2010.

This award includes a carryover of \$638,174 (\$595,497 Direct Costs; \$42,677 F&A Costs) from the 07 year to the 09 year. These funds are restricted for the purpose requested in the letter of 07/15/2010 from UCSF, and may not be rebudgeted or used for other purposes.

This revised award includes funds to support consortium activity with Oregon Health Sciences University in the amount of \$75,694 (\$57,344 direct costs + \$18,350 facilities and administrative costs), Willamette Family in the amount of \$91,363 (\$75,258 direct costs + \$16,105 facilities and administrative costs), ADAPT, Inc. in the amount of \$154,617 (\$154,617 direct costs + \$0 facilities and administrative costs), La Frontera in the amount of \$155,974 (\$137,543 direct costs + \$18,431 facilities and administrative costs), BiValley Medical Clinic in the amount of \$17,485 (\$15,204 direct costs + \$2,281 facilities and administrative costs), Public Health Foundation Enterprises, Inc. (PHFE) in the amount of \$53,704 (\$49,726 direct costs + \$3,978 facilities and administrative costs), and City and County of San Francisco (CCSF) in the amount of \$16,876 (\$15,068 direct costs + \$1,808). Consortia are to be established and administered as described in the NIH Grants Policy Statement (NIH GPS). The referenced section of the NIH Grants Policy Statement is available at http://grants1.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part12.htm#_Toc54600251, pages 224-227.

In addition, this award acknowledges receipt and NIDA's acceptance of the Data and Safety Monitoring Plans submitted 10/4/2010 by Ms. Alina Leong, UCSF.

The below restriction remains in effect.

**** THIS AWARD CONTAINS GRANT SPECIFIC RESTRICTIONS. THESE RESTRICTIONS MAY ONLY BE LIFTED BY A REVISED NOTICE OF GRANT AWARD.

Salary and fringe dollars in the amount of \$30,000 (and associated F&A) requested for TBD Various Investigators/Affiliated Investigators & Trainees are restricted until detailed information is provided by the grantee's signing official to NIDA's Grants Management Branch. The NIDA will notify the grantee via a revised Notice of Grant Award (NGA) when these NIH administrative requirements have been met.

This award is issued as a Cooperative Agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the Terms and Conditions of Award as set forth in the SPECIAL REQUIREMENTS section of RFA-DA-10-009, "The National Drug Abuse Treatment Clinical Trials Network (U10)," release date 06/01/2009, which are hereby incorporated by reference as special terms and conditions of this award. This RFA may be accessed at: <http://grants.nih.gov/grants/guide/index.html> or obtained from the Grants Management Contact referenced on the award.

The following principal investigators (PIs) are associated with this project: Dr. James L. Sorensen, University of California, San Francisco, and Dr. Dennis McCarty, Oregon Health & Science University. Dr. Sorensen is the contact PI for correspondence purposes.

Prior Approvals: Consistent with NOT-OD-06-054, (<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-054.html>), as this grant has multiple Principal Investigators (PIs), although the signatures of the PIs are not required on prior approval requests submitted to the agency, the grantee institution must secure and retain the signatures of all of the PIs within their own internal processes.

The award amount for the current year is based upon IRG/Council recommendations, cost analysis, program priorities and availability of funds. Future year levels were calculated not to exceed a 3% incremental increase in recurring costs.

This award includes funds awarded for consortium activity with Oregon Health & Science University in the amount of \$473,009 (\$358,340 direct costs + \$114,669 facilities and administrative costs); East Bay Community Recovery in the amount of \$12,000 (\$10,000 direct costs + \$2,000 facilities and administrative costs); Kaiser Permanente Northwest in the amount of \$15,800 (\$10,000 direct costs + \$5,800 facilities and administrative costs); LaFrontera Center in the amount of \$11,340 (\$10,000 direct costs + \$1,340 facilities and administrative costs); Oregon Treatment Network in the amount of \$13,000 (\$10,000 direct costs + \$3,000 facilities and administrative costs); and Signal Behavioral Health Network (Denver) in the amount of \$12,500 (\$10,000 direct costs + \$2,500 facilities and administrative costs). Consortia are to be established and administered as described in the NIH Grants Policy Statement (NIH GPS). The referenced section of the NIH Grants Policy Statement is available at http://grants1.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part12.htm#_Toc54600251, pages 224-227.

None of the funds in this award shall be used to pay the salary of an individual at a rate in excess of the current salary cap. Therefore, this award and/or future years are adjusted accordingly, if applicable. Current salary cap levels can be found at the following: http://grants2.nih.gov/grants/policy/salcap_summary.htm.

Grantee is reminded that using grant funds for food as part of meeting expenses must meet the allowability definition as set forth in OMB Circular A-21.

This award is subject to the current Data and Safety Monitoring (DSM) plans submitted and previously approved by NIDA. Any changes in the DSM plans must be reviewed and approved by the Program Official. If changes are approved, the approval will be reflected on the Notice of Grant Award. If changes are not approved, the Principal Investigator will be requested to revise the DSM plans to the satisfaction of the Program Official. The Principal Investigator must provide a DSM plan for any new trial that is to be conducted under this grant. The amended DSM plan for each new

trial must be submitted to the Grants Management Specialist listed below, directly from or signed by the grantee Signing Official.

These policies, which have been published in the NIH Guide for Grants and Contracts, can be found at the following websites:

<http://grants.nih.gov/grants/guide/notice-files/not98-084.html>;
<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-038.html>
<http://www.nida.nih.gov/Funding/DSMBSOP.html>

Grantee is reminded of the requirement for education in the protection of human research participation. This requirement can be satisfied by completing the on-line tutorial Protecting Human Research Participants (<http://phrp.nihtraining.com>). Additional details on this requirement can be found at NIH Notice NOT-OD-08-054, "Guidance on NIH Office of Extramural Research (OER) on-line tutorial Protecting Human Research Participants (PHRP)."

Grantee is reminded that IRB approval(s) are required for each new protocol and performance site prior to implementation of human subjects research. No funds may be drawn down from the payment system and no obligations may be made against Federal funds for research involving human subjects at any site engaged in such research for any period not covered by an Office for Human Research Protections Assurance and an IRB approval consistent with the requirements of 45 CFR Part 46.

Failure to comply with the above requirements may result in suspension and/or termination of this award, withholding of support, audit disallowances, and/or other appropriate action. See the NIH Grants Policy Statement, December 2003, (http://grants2.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part5.htm), pages 54-56 for specific requirements related to the protection of human subjects, which are applicable to and a term and condition of this award.

All grantees must acknowledge funding received from the National Institute on Drug Abuse at the National Institutes of Health when issuing statements, press releases, requests for proposals, bid solicitations, and other documents describing projects or programs funded in whole or in part with NIDA money. (NIH Grants Policy Statement, Part II, Page 114- Rights in Data (Publication and Copyrighting), December 2003).

In conjunction with this requirement, in order to most effectively disseminate research results, advance notice should be given to NIDA that research finds are about to be published so that we may coordinate accurate and timely release to the media. This information will be embargoed until the publication date. Any press notification should be coordinated with the NIDA Press Officer who can be reached at (301) 443-6245.

We strongly encourage all of our grantees to register in the eRA Commons. The eRA Commons provides grantees with the ability to electronically submit; e-SNAP applications, No cost extensions, Just in Time documents, Financial Status Reports, Final Progress Reports, and allows grantees to register to become e-mail enabled to receive Notice of Grant Awards (NGA).

NIDA has an interest in supporting HIV/AIDS and infectious disease research. The purpose of this support is to develop effective prevention, treatment, and service strategies for drug abusing youth and adults. To that end, awardees conducting HIV/AIDS research are encouraged to make every effort to incorporate scientific questions related to HIV/AIDS and other infectious diseases into research protocols. Principal Investigators will be required to provide information related to the development of research in this area in annual progress reports to allow NIDA to assess progress regarding HIV/AIDS research.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Deborah S Wertz

Email: dw80c@nih.gov Phone: (301) 649-1715 Fax: (301) 594-6849

Program Official: Ronald Dobbins
 Email: rdobbins@nida.nih.gov Phone: 301 443-6697 Fax: 301-443-2317

SPREADSHEET SUMMARY
GRANT NUMBER: 2U10DA015815-09 REVISED

INSTITUTION: UNIVERSITY OF CALIFORNIA SAN FRANCISCO

<i>Budget</i>	<i>Year 9</i>	<i>Year 10</i>	<i>Year 11</i>	<i>Year 12</i>	<i>Year 13</i>
Salaries and Wages	\$299,460	\$284,508	\$284,508	\$284,508	\$284,508
Fringe Benefits	\$76,685	\$72,652	\$72,652	\$72,652	\$72,652
Personnel Costs (Subtotal)	\$376,145	\$357,160	\$357,160	\$357,160	\$357,160
Consultant Services	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000
Supplies	\$3,975	\$3,600	\$3,600	\$3,600	\$3,600
Travel Costs	\$50,375	\$50,000	\$50,000	\$50,000	\$50,000
Other Costs	\$55,949	\$45,900	\$45,900	\$45,900	\$45,900
Consortium/Contractual Cost	\$1,103,362	\$537,649	\$537,649	\$537,649	\$537,649
TOTAL FEDERAL DC	\$1,599,806	\$1,004,309	\$1,004,309	\$1,004,309	\$1,004,309
TOTAL FEDERAL F&A	\$182,115	\$130,962	\$116,995	\$116,132	\$116,132
TOTAL COST	\$1,143,747	\$1,135,271	\$1,121,304	\$1,120,441	\$1,120,441

<i>Facilities and Administrative Costs</i>	<i>Year 9</i>	<i>Year 10</i>	<i>Year 11</i>	<i>Year 12</i>	<i>Year 13</i>
F&A Cost Rate 1	26%	26%	26%	26%	26%
F&A Cost Base 1	\$700,444	\$503,700	\$449,980	\$446,660	\$446,660
F&A Costs 1	\$182,115	\$130,962	\$116,995	\$116,132	\$116,132



"Anthony, Jude"
<Jude.Anthony@ucsf.edu>
12/09/2010 09:50 AM

To "Cheung, Diana (DPH)" <Diana.Cheung@sfdph.org>
cc "Sorensen, James" <James.Sorensen@ucsf.edu>,
"Paschke, Barbara" <Barbara.Paschke@ucsf.edu>
bcc
Subject Subaward 6422sc [Colfax SubPI; Sorensen UCSF PI]

Dear Diana Cheung:

Enclosed is proposed Subaward 6422sc – between UCSF and City and County of San Francisco.

If acceptable, please have a signed copy of the agreement returned to me – via PDF. Thank you.

Please indicate the Subaward number, 6422sc, on all invoices and correspondence related to this agreement and also place the DPA and Fund numbers on all invoices. For questions regarding the administration of this project please contact Barbara.Paschke@ucsf.edu / 415-437-3032. For questions regarding the terms and conditions of this subcontract, please contact me. If you have questions regarding invoices please contact the accounting department/subcontracts, subcontract@ucsf.edu / +415-476-2126.

Jude Anthony, MA
Contracts/Grants Analyst III
Office of Sponsored Research
University of California, San Francisco
Campus Mailbox 0962
3333 California Street, Suite 315
San Francisco, California 94143-0962
v. 415.476.8151 | f. 415.476.8158
jude.anthony@ucsf.edu | www.research.ucsf.edu/CG/index.asp



6422sc.PDF

INTRODUCTION FORM

By a member of the Board of Supervisors or the Mayor

Time Stamp or
Meeting Date

I hereby submit the following item for introduction:

- 1. For reference to Committee:
 An ordinance, resolution, motion, or charter amendment
- 2. Request for next printed agenda without reference to Committee
- 3. Request for Committee hearing on a subject matter
- 4. Request for letter beginning "Supervisor _____ inquires..."
- 5. City Attorney request
- 6. Call file from Committee
- 7. Budget Analyst request (attach written motion).
- 8. Substitute Legislation File Nos.
- 9. Request for Closed Session
- 10. Board to Sit as A Committee of the Whole

Please check the appropriate boxes. The proposed legislation should be forwarded to the following:

- | | |
|---|--|
| <input type="checkbox"/> Small Business Commission | <input type="checkbox"/> Youth Commission |
| <input type="checkbox"/> Ethics Commission | <input type="checkbox"/> Planning Commission |
| <input type="checkbox"/> Building Inspection Commission | |

Note: For the Imperative Agenda (a resolution not on the printed agenda), use a different form.]


Sponsor(s): Wiener

SUBJECT: Accept and Expend Grant - Western States Node of the National Drug Abuse Treatment Clinical Trials Network - \$16,876

The text is listed below or attached:

Resolution authorizing the San Francisco Department of Public Health to accept and expend retroactively a grant in the amount of \$16,876 from the University of California San Francisco, to participate in a program entitled "Western States Node of the National Drug Abuse Treatment Clinical Trials Network;" for the period of September 1, 2010, through August 31, 2011.

Signature of Sponsoring Supervisor: _____



For Clerk's Use Only: